PTPN1/2 PROTAC X1   Click here for help

GtoPdb Ligand ID: 14701

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This compound is a cereblon-based dual PROTAC of the phosphatase proteins protein tyrosine phosphatase non-receptor type 1 (PTPN1; PTP1B) and protein tyrosine phosphatase non-receptor type 2 (PTPN2; TCPTP) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 23
Hydrogen bond donors 9
Rotatable bonds 32
Topological polar surface area 332.33
Molecular weight 1313.14
XLogP -1.17
No. Lipinski's rules broken 4

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC=C(C=C1Br)C(=O)NCCCC[C@@H](C(=O)N2CCN(CCC(=O)NC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)CC2)NC(=O)[C@H](CC6=CC=C(C=C6)C(F)(F)P(=O)(O)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)CC8=CC=C(C(=C8)OC)O
Isomeric SMILES O=C(NC1=CC=CC2=C1CN(C3C(NC(CC3)=O)=O)C2=O)CCN4CCN(C([C@@H](NC([C@H](CC5=CC=C(C=C5)C(F)(P(O)(O)=O)F)NC([C@H](CC6=CC=CC=C6)NC(CC7=CC(OC)=C(C=C7)O)=O)=O)=O)CCCCNC(C=8C=C(Br)C(=CC8)C)=O)=O)CC4
InChI InChI=1S/C62H69BrF2N9O14P/c1-37-14-18-41(35-45(37)63)56(79)66-25-7-6-12-47(61(84)73-29-27-72(28-30-73)26-24-54(77)67-46-13-8-11-43-44(46)36-74(60(43)83)50-21-23-53(76)71-59(50)82)69-58(81)49(32-39-15-19-42(20-16-39)62(64,65)89(85,86)87)70-57(80)48(31-38-9-4-3-5-10-38)68-55(78)34-40-17-22-51(75)52(33-40)88-2/h3-5,8-11,13-20,22,33,35,47-50,75H,6-7,12,21,23-32,34,36H2,1-2H3,(H,66,79)(H,67,77)(H,68,78)(H,69,81)(H,70,80)(H,71,76,82)(H2,85,86,87)/t47-,48-,49-,50?/m0/s1
InChI Key MFNIHFVEEOWKIR-BNWZHACUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Immunopharmacology Comments
Concomitant inhibition of the phosphatase activity of PTPN1 and -2 is proposed for cancer immunotherapy, based on the roles of these enzymes in regulating T cell activation and tumour antigen presentation.